Literature DB >> 7193106

Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma.

M K Romach, K M Piafsky, J G Abel, V Khouw, E M Sellers.   

Abstract

The distribution of basic drugs in blood differs qualitatively from that of acidic drugs. The binding of racemic, d-methadone, and l-methadone to human plasma and isolated protein fractions was studied by equilibrium dialysis at 37 degrees. In plasma samples from 29 healthy subjects free fraction of dl-methadone was (mean% +/- SD) 10.62 +/- 1.43. There were significant variations among subjects (p less than 0.001). The free fraction of the d-isomer was 9.24 +/- 1.61% and of the l-isomer, 12.44 +/- 1.53%. Plasma albumin concentration and degree of binding do not correlate, but in normal hypoalbuminemic subjects the free fraction of dl-methadone correlates negatively with the concentration of alpha 1-acid glycoprotein (alpha 1-AGP), an acute-phase reactant protein. Percentage dl-methadone bound to purified human serum albumin (HSA) (4.1 mg/dl) was 36.60% (mean +/- SD). Isolated alpha 1-AGP bound dl-methadone more avidly. As the alpha 1-AGP increased from 0.05 to 2.0 gm/l, free fraction fell from 92.40% to 8.80%. Addition of alpha 1-AGP (0.05 to 2.0 gm/l) to a physiologic concentration of purified HSA or to whole plasma progressively increased methadone binding. In eight monozygotic twin pairs, within-pair differences in binding of dl-methadone were less than in eight dizygotic twin pairs. Less than 20% of naloxone, codeine, morphine, heroin, pentazocine, and diphenoxylate bound to alpha 1-AGP. Elevations of alpha 1-AGP that occur in a variety of diseases may alter the kinetic and pharmacologic activity of methadone.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7193106     DOI: 10.1038/clpt.1981.34

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  31 in total

1.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 2.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

3.  [Not Available].

Authors:  J Jage
Journal:  Schmerz       Date:  1989-09       Impact factor: 1.107

4.  Determination of the unbound fraction of R- and S-methadone in human brain.

Authors:  Karen M D Holm; Kristian Linnet
Journal:  Int J Legal Med       Date:  2016-04-07       Impact factor: 2.686

5.  Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein.

Authors:  C B Eap; C Cuendet; P Baumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-02       Impact factor: 3.000

Review 6.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Pharmacokinetics of intravenously administered 125I-labelled human alpha 1-acid glycoprotein.

Authors:  F Brée; G Houin; J Barré; J L Moretti; V Wirquin; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

9.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

10.  Pharmacokinetic interaction between telaprevir and methadone.

Authors:  Rolf van Heeswijk; Peter Verboven; Ann Vandevoorde; Petra Vinck; Jan Snoeys; Griet Boogaerts; Els De Paepe; Rodica Van Solingen-Ristea; James Witek; Varun Garg
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.